An alpha--particle irradiator, enabling high--precision irradiation of cells for in--vitro studies, has been constructed. The irradiation source was a 241 Am source, on which well inserts containing cancer cells growing in monolayer were placed. The total radioactivity, uniformity, and alpha--particle spectrum were determined by use of HPGe--detector, Gafchromic™--dosimetry film, and PIPS®--detector measurements, respectively. Monte Carlo simulations were used for dosimetry. Three prostate cancer (LNCaP, DU145, PC3) and three pancreatic cancer (Capan--1, Panc--1, BxPC--3) cell lines were irradiated by alpha particles to the absorbed doses 0, 0.5, 1, and 2 Gy. For reference, cells were irradiated using 137 Cs to the absorbed doses 0, 1, 2, 4, 6, 8, and 10 Gy. Radiation sensitivity was estimated using a tetrazolium salt--based colorimetric assay with absorbance measurements at 450 nm. The relative biological effectiveness for alpha particles relative to gamma irradiation at 37% cell survival for the LNCaP, DU145, PC3, Capan--1, Panc--1, and BxPC--3 cells were 7.9 ± 1.7, 8.0 ± 0.8, 7.0 ± 1.1, 12.5 ± 1.6, 9.4 ± 0.9, and 6.2 ± 0.7, respectively. The results show the feasibility of constructing a desk--top alpha--particle irradiator, as well as indicate that both prostate and pancreatic cancers are good candidates for further studies of alpha--particle radioimmunotherapy.